Starpharma Holdings Limited (ASX:SPL)
0.6800
-0.0150 (-2.16%)
Apr 20, 2026, 3:59 PM AEST
Starpharma Holdings Revenue
Starpharma Holdings had revenue of 11.16M AUD in the half year ending December 31, 2025, with 39.00% growth. This brings the company's revenue in the last twelve months to 14.58M, up 250.60% year-over-year. In the fiscal year ending June 30, 2025, Starpharma Holdings had annual revenue of 5.85M, down -40.04%.
Revenue (ttm)
14.58M
Revenue Growth
+250.60%
P/S Ratio
20.08
Revenue / Employee
364.45K
Employees
40
Market Cap
292.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.85M | -3.91M | -40.04% |
| Jun 30, 2024 | 9.76M | 5.41M | 124.64% |
| Jun 30, 2023 | 4.34M | -819.00K | -15.87% |
| Jun 30, 2022 | 5.16M | 1.68M | 48.04% |
| Jun 30, 2021 | 3.49M | -3.63M | -50.99% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 96.30M |
| Orthocell | 9.33M |
| Immutep | 7.92M |
| Dimerix | 7.42M |
| Actinogen Medical | 7.36M |
| Alterity Therapeutics | 6.64M |
| Racura Oncology | 3.48M |
| Tetratherix | 2.00M |
Starpharma Holdings News
- 3 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 4 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 4 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 4 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 5 years ago - Starpharma signs DEP® ADC Research Agreement with MSD - PRNewsWire
- 6 years ago - Starpharma to Webcast Live at Life Sciences Investor Forum September 17th - GlobeNewsWire
- 6 years ago - Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2 - Business Wire
- 6 years ago - Starpharma creates slow release soluble DEP remdesivir nanoparticle - Business Wire